| Cat. No. |
Product Name |
Information |
| PC-60038 |
Derazantinib
FGFR inhibitor
|
Derazantinib (ARQ-087) is a novel potent, ATP competitive multi-kinase inhibitor with IC50 of FGFR1/2/3 with IC50 of 1.8-4.5 nM. |
| PC-45474 |
FIIN-2
FGFR inhibitor
|
FIIN-2 is a potent, irreversible inhibitor of FGFR with IC50 values of 3.1/ 4.3/27/45 nM for FGFR1/2/3/4. |
| PC-45475 |
FIIN-3
FGFR/EGFR inhibitor
|
FIIN-3 is a selective, next-generation, covalent dual FGFR/EGFR inhibitor (IC50=1-60 nM). |
| PC-42567 |
SU5402
Tyrosine kinase inhibitor
|
SU5402 is a multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively. |
| PC-42521 |
PD173074
FGFR1 inhibitor
|
PD173074 is a potent, selective, ATP-competitive FGFR1 inhibitor with IC50 of ~25 nM. |
| PC-42217 |
FGFR4-IN-1
FGFR4 inhibitor
|
FGFR4-IN-1 is a potent, selective inhibiotr of FGFR4 with IC50 of 0.7 nM, significantly inhibits the proliferation of HuH-7 cells with IC50 of 7.8 nM. |
| PC-45761 |
Zoligratinib
FGFR inhibitor
|
CH-5183284 (Debio-1347, Debio1347) is a potent, selective and orally available FGFR1/2/3 inhibitor with enzyme IC50 of 9.3/7.6/22 nM, respectively. |
| PC-43499 |
AZD4547
FGFR inhibitor
|
Fexagratinib (AZD4547, ADSK091) is a potent and selective inhibitor of FGFR1/2/3 with IC50s of 0.2/1.8/2.5 nM, respectively. |
| PC-45899 |
Dovitinib
Multikinase inhibitor
|
Dovitinib (CHIR-258, TKI258) is a multitargeted RTK inhibitor of class III, IV, and V RTKs with IC50 of 1/2/36/8/9 nM for FLT3/c-KIT/c-Fms/FGFR1/FGFR3, respectively. |
| PC-42452 |
Dovitinib lactate
Multikinase inhibitor
|
Dovitinib lactate (CHIR-258, TKI-258) is a multitargeted RTK inhibitor of class III, IV, and V RTKs with IC50 of 1/2/36/8/9 nM for FLT3/c-KIT/c-Fms/FGFR1/FGFR3, respectively. |
| PC-42173 |
BLU-554
FGFR4 inhibitor
|
BLU-554 (Fisogatinib, BLU554) is a novel potent, highly selective and orally bioavailable inhibitor of FGFR4 with IC50 of 5 nM. |
| PC-42401 |
SUN11602
bFGF mimic
|
A novel aniline compound that mimics the neuroprotective effects of bFGF by activating FGFR1-MEK/ERK signaling pathway. |
